Trial Review

The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12605000736640
Ethics application status
Approved
Date submitted
13/09/2005
Date registered
11/11/2005
Date last updated
30/08/2024
Date data sharing statement initially provided
30/08/2024
Type of registration
Retrospectively registered

Titles & IDs
Public title
DETECTION OF EARLY CARDIAC (ASYMPTOMATIC) DISEASE BY B-TYPE NATRIURETIC PEPTIDE (DETECT STUDY).
Scientific title
DETECTION OF EARLY CARDIAC (ASYMPTOMATIC) DISEASE BY B-TYPE NATRIURETIC PEPTIDE (DETECT STUDY).
Universal Trial Number (UTN)
Trial acronym
DETECT
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Early Cardiac Disease 888 0
Condition category
Condition code
Cardiovascular 956 956 0 0
Other cardiovascular diseases

Intervention/exposure
Study type
Observational
Patient registry
Target follow-up duration
Target follow-up type
Description of intervention(s) / exposure
None.
Intervention code [1] 554 0
None
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 1256 0
To test the ability of plasma NT-proBNP and/or BNP to distinguish early structural and/or functional cardiac changes (including increased left ventricular mass and abnormal diastolic function) in asymptomatic groups at risk of later adverse cardiac outcomes.
Timepoint [1] 1256 0
Secondary outcome [1] 2291 0
Timepoint [1] 2291 0

Eligibility
Key inclusion criteria
Study Population: Fifty asymptomatic patients aged 45-65 years with treated or untreated hypertension of 10 or more years duration any of whom may or may not have additional risk factors, including diabetes, dyslipidaemia, obesity. No patient will have incurred any overt cardiovascular event (ie. no acute coronary syndrome, no stable angina, no heart failure, no cerebrovascular events and no peripheral arterial events).Control Group: Fifty age, gender and BMI-matched unmedicated controls with no history of cardiovascular risk factors or events and with normal findings on physical examination. Both groups will have normal renal function.
Minimum age
45 Years
Maximum age
65 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
No exclusion criteria

Study design
Purpose
Natural history
Duration
Longitudinal
Selection
Defined population
Timing
Prospective
Statistical methods / analysis

Recruitment
Recruitment status
Active, not recruiting
Date of first participant enrolment
Anticipated
1/02/2005
Actual
1/02/2005
Date of last participant enrolment
Anticipated
Actual
13/12/2005
Date of last data collection
Anticipated
31/12/2030
Actual
Sample size
Target
100
Accrual to date
Final
100
Recruitment outside Australia
Country [1] 215 0
New Zealand
State/province [1] 215 0

Funding & Sponsors
Funding source category [1] 1054 0
Commercial sector/Industry
Name [1] 1054 0
Roche Diagnostics
Country [1] 1054 0
New Zealand
Primary sponsor type
Commercial sector/Industry
Name
Roche Diagnostics
Address
Country
Switzerland
Secondary sponsor category [1] 915 0
University
Name [1] 915 0
Christchurch Cardioendocrine Research Group
Address [1] 915 0
Country [1] 915 0
New Zealand

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 2353 0
Southern Health and Disability Ethics Committee
Ethics committee address [1] 2353 0
Ethics committee country [1] 2353 0
New Zealand
Date submitted for ethics approval [1] 2353 0
Approval date [1] 2353 0
24/04/2005
Ethics approval number [1] 2353 0
URB/04/12/010

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 35917 0
Professor Richard Troughton
Address 35917 0
Christchurch Heart Institute
University of Otago, Christchuch
PO Box 4345
Christchurch 2014
Country 35917 0
New Zealand
Phone 35917 0
+643 3640640
Fax 35917 0
Email 35917 0
Richard [email protected]
Contact person for public queries
Name 9743 0
Dr Richard Troughton
Address 9743 0
Department of Medicine
Christchurch School of Medicine & Health Sciences
PO Box 4345
Christchurch 8015
Country 9743 0
New Zealand
Phone 9743 0
+64 3 3640640
Fax 9743 0
+64 3 3641115
Email 9743 0
[email protected]
Contact person for scientific queries
Name 671 0
Lorraine Skelton
Address 671 0
Department of Medicine
Christchurch School of Medicine & Health Sciences
PO Box 4345
Christchurch 8015
Country 671 0
New Zealand
Phone 671 0
+64 3 3640640
Fax 671 0
+64 3 3641115
Email 671 0
[email protected]

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
No/undecided IPD sharing reason/comment


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.